Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu; Yaling Hu; Miao Xu; Zhen Chen; Wanqi Yang; Zhiwei Jiang; Minjie Li; Hui Jin; Guoliang Cui; Panpan Chen; Lei Wang; Guoqing Zhao; Yuzhu Ding; Yuliang Zhao; Weidong Yin

doi:10.1016/s1473-3099(20)30987-7

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu(Hebei Provincial Center for Disease Control and Prevention), Yaling Hu(Sinovac Biotech), Miao Xu(National Institutes for Food and Drug Control), Zhen Chen(National Institutes for Food and Drug Control), Wanqi Yang(Sinovac Biotech), Zhiwei Jiang, Minjie Li(Hebei Provincial Center for Disease Control and Prevention), Hui Jin(Hebei Provincial Center for Disease Control and Prevention), Guoliang Cui, Panpan Chen(Hebei Provincial Center for Disease Control and Prevention), Lei Wang(Sinovac Biotech), Guoqing Zhao, Yuzhu Ding(Hebei Provincial Center for Disease Control and Prevention), Yuliang Zhao(Hebei Provincial Center for Disease Control and Prevention), Weidong Yin(Sinovac Biotech)

The Lancet Infectious Diseases

February 5, 2021

10.1016/s1473-3099(20)30987-7

Cited by 574Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis